Merck & Co., Inc. 4

EVP & Pres. MMD David R. Maraldo exercised options and sold 18,706 shares of Merck & Co., Inc. (MRK) common stock on August 5, 2026 in same‑day transactions.

On August 5, 2026, Merck & Co., Inc. EVP & President, MMD, David R. Maraldo exercised three tranches of stock options covering a total of 18,706 shares of common stock at exercise prices of $73.73, $87.10, and $84.71 per share, then sold the same total number of shares in market transactions at a weighted average price of $128.7179 per share (within a range of $128.64–$128.85). The option exercises (Form 4 code M) and same‑day sales (code S) indicate a cashless or liquidity‑driven transaction rather than an open‑market accumulation or disposal, leaving him with 18,212.434 shares of Merck common stock held directly after the trades. The options exercised relate to grants originally made in 2022, 2023, and 2026 with standard three‑year vesting schedules described in the footnotes, and the filing suggests these are routine compensation‑related transactions, though the dollar value of the sales is sizable.

Filing Facts

CIK

310158

Ticker

MRK

Form

4

Source Type

fda

Accession

0000310158-26-000215

Alert Tier

6